IAIM
VERV

International Assets Investment Management’s Verve Therapeutics VERV Stock Holding History

International Assets Investment Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-500
Closed -$2.42K – 1906
2024
Q3 		$2.42K Hold
500
– – ﹤0.01% 1692
2024
Q2 		$2.44K Buy
+500
New +$3.14K ﹤0.01% 1977

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

International Assets Investment Management's VERV Position: Q4 2024 in Review

International Assets Investment Management sold out of Verve Therapeutics (VERV) in Q4 2024, closing a stake of 500 shares — an estimated $2.42K sold.

International Assets Investment Management first reported a position in VERV in Q2 2024 and held it in 2 quarters. The position peaked at $2.44K in Q2 2024. 166 funds tracked by Wall St. Rank hold VERV as of Q4 2024.

  • International Assets Investment Management reported no remaining Verve Therapeutics position as of Q4 2024 after selling out during the quarter.
  • International Assets Investment Management sold 500 Verve Therapeutics shares in Q4 2024, an estimated $2.42K.
  • International Assets Investment Management first reported a position in Verve Therapeutics in Q2 2024 and held it in 2 quarters.
  • International Assets Investment Management's Verve Therapeutics position peaked at $2.44K in Q2 2024.
  • 166 funds tracked by Wall St. Rank held Verve Therapeutics as of Q4 2024.

Based on International Assets Investment Management's 13F filing for Q4 2024, filed 8 Jan 2025.